Everest : China Approves IND Application For Phase 1b Study Of EVER001 In Glomerular Diseases

Everest Medicines said that the China National Medical Products Administration (NMPA)'s Center for Drug Evaluation has approved the Investigational New Drug (IND) application for a Phase 1b study of EVER001, a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor, in development for the treatment of glomerular diseases.

The company noted that the planned Phase 1b clinical study will evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of EVER001 in patients in China with glomerular disease characterized by proteinuria, a common cause of chronic kidney disease.

Under a licensing agreement with Sinovent Pharmaceuticals and SinoMab BioScience in September 2021, Everest owns the global rights to develop, produce and commercialize EVER001 for the treatment of renal diseases.

Based on a Phase 1 study in healthy subjects in China conducted by SinoMab, EVER001 exhibited high selectivity, excellent pharmacokinetics properties and safety profile as well as robust target engagement.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Japanese auto major Toyota Motor Corp. has retained its title as the world's top selling automaker in fiscal 2022 for the third straight year, by selling around 10.5 million vehicles. The global sales were nearly flat with last year amid solid demand centered around Asia, while global production grew with increased capacity and production optimization in North America and Asia. Dutch consumer electronics giant Philips Electronics NV reported Monday a loss in its fourth quarter, compared to prior year's profit, even as sales increased. The company further declared a dividend, and said its order book remains strong. Going ahead, the company projects comparable sales growth in fiscal 2023, 2025, and beyond. Sovos Brands Intermediate, Inc. is recalling a limited number of 16-ounce jars of Rao's Made for Home Slow Simmered Soup, Chicken & Gnocchi citing undeclared egg, an allergen, the U.S. Food and Drug Administration said. The affected soup is labeled as Chicken & Gnocchi, but will contain vegetable minestrone, which is dark red.
Follow RTT